Porcine Vaccines Market Research Report - Forecast till 2027

Porcine Vaccines Market Research Report: by Type (Inactivated Vaccines, DNA Vaccines), Disease Indication (Diarrhea, Swine Influenza), End User - Forecast Till 2027

ID: MRFR/HC/5969-HCR | February 2021 | Region: Global | 90 pages

Porcine Vaccines Market Scenario


Porcine vaccines market is expected to grow significantly over the forecast period. The porcine vaccines market held a market value of USD 1910.7 million in 2017 and is projected to grow at a CAGR of 7.1% over the forecast period. Porcine vaccine is an administrative and clinical drug which helps in improving swine health and protects against deadly viruses and pathogens. Porcine vaccines offer wide range of benefits for the treatment of swine diseases. The rising incidences of swine diseases such as PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), swine influenza etc. is expected to boost the growth of the market over the forecast period.

Moreover, rising number of biotechnology companies, research organizations engaged in research and development of porcine vaccines, and government initiatives for funding agriculture and animal husbandry sector and rising demand for porcine meat and gelatine are driving the growth of this market. For instance, European Union is the third country in the world by per-capita pig meat consumption, with an average of 88.9 kilos of meat consumed in 2017. Despite the drivers, the high storage cost of vaccines may hinder the market growth during the assessment period.


Segmentation


The porcine vaccines market has been segmented into type, disease indication, and end user.


By type, the market has been segmented into Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines.


On the basis of disease indication, the market has been segmented into PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD) and others.


The market, by end user, has been segmented into Veterinary Hospitals and Hog Production Farm.


The porcine vaccines market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The porcine vaccines market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.


The European porcine vaccines market has been segmented into Western Europe and Eastern Europe. The Western Europe porcine vaccines market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The porcine vaccines market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The porcine vaccines market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Porcine Vaccines Systems Share (%), by Region, 2017
Global Procine Vaccines Systems Share by Region 2017


Source: White Papers, Company Presentations, Annual Reports


Geographically, the Americas is anticipated to dominate the global porcine vaccines market owing to the rise in number of pig farms and rise in swine diseases such as PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), swine influenza etc. Moreover, rapid increase in contract farming and independent farming for pig cultivation is driving the growth of this market in this region. According to a report from National Hog Farmer, there were 71.7 million pigs in US hog farms as of June 2016.


Europe is expected to hold the second largest position in the global porcine vaccines market. The market growth in this region is attributed to increasing number of production units for swine and high consumption of pork meat.


The porcine vaccines market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to initiatives by various government agencies, animal associations, and high growth opportunities for major key players for setting up their vaccine manufacturing plants in this region.


The Middle East & Africa has the lowest share of the global porcine market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the animal care sector.


Porcine Vaccines Market, by Type



  •  Inactivated vaccines

  • Live attenuated vaccines

  • Toxoid vaccines

  • Recombinant vaccines

  • Conjugate vaccines

  • DNA vaccines


Porcine Vaccines Market, by Disease Indication



  • PED (Porcine Epidemic Diarrhea)

  • PRRS (Porcine Reproductive & Respiratory Syndrome)

  • Swine influenza

  • Aujeszky's disease (AD)

  • Porcine Circovirus Associated Disease (PCVAD)

  • Others


Porcine Vaccines Market, by End-user



  • Veterinary Hospitals

  • Hog Production Farm


Porcine Vaccines Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America



  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe



  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • The Middle East & Africa

    • Middle East

    • Africa




Porcine Vaccines Market, by Key Players



  • Bayer AG

  • Bimeda, Inc.

  • Boehringer Ingelheim International GmbH

  • Ceva Sante Animale

  • Eli Lilly and Company

  • Merck & Co., Inc.

  • Sanofi S.A.

  • Vetoquinol S.A.

  • Zoetis, Inc.

  • PBS Animal Health

  • Aptimmune


Intended Audience



  • Porcine vaccines manufacturers

  • Porcine vaccines suppliers

  • Private research laboratories

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Government research laboratories

  • Contract manufacturing organizations



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2017: USD 1910.7 Million
  • 2027: Significant Value
  •   CAGR   7.1% (2018-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Disease indication, and End user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Bayer AG, Bimeda, Inc., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A., Vetoquinol S.A.,Zoetis, Inc., PBS Animal Health, Aptimmune
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Rising number of biotechnology companies
  • Research organizations engaged in research and development of porcine vaccines
  • Government initiatives for funding agriculture and animal husbandry sector
  • Rising demand for porcine meat and gelatine




  • This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.